Lattice Medical

TECHNOLOGY

Lattice Medical is a biomedical start-up that was launched in October 2017
Patented 3D technology developed with CHU Lille-France that allows adipose tissue to naturally regenerate

Breast cancer touch 1 in 8 women in the world In 40% of cases, mastectomy is the usual treatment followed by chemotherapy or radiotherapy
Only 14% of women receive reconstructive surgery
01
08
Reconstruction procedure offered are:
silicon prosthesis, autologous fat tissues grafting by microsurgical technics (DIEP) or non-vascularise transfer (lipofilling).

These methods show different issues such as multiple surgical procedure, complications and costs for healthcare system, limiting the availability for patients.
02
08
LATTICE MEDICAL, valorising 6 research years from CHU Lille, comes up with an innovative technical solution combining the advantages of current techniques, thereby simplifying the process and making it more accessible and less expensive: a 3D printed bioabsorbable implant called MATTISSE.
03
08
The technology involves the use of autologous adipose tissue as a base, and then combines this with a 3D printed absorbable implant, thereby making it possible to get the desired size with just one operation. This implant helps the patient’s fat cells regenerate.
04
08
MATTISSE is made up of two 3D printed bioabsorbable parts: the first, inspired by Calais laces, provides support for the fat, and the second is a shell giving the volume and the shape reconstruction.

The use of 3D printing makes it possible, using MRI or CT-scan images, to design a personalised implant to restore former breast.
05
08
Autologous fat tissues are placed on the support material. It helps guide tissue reconstruction during 4 to 8 months. Meanwhile, the bioabsorbable implant will slowly degrade, until full resorption in one year. The breast is thus entirely rebuilt by the patient’s tissues, without introducing any foreign bodies.
06
08
LATTICE MEDICAL’s ambition is to make and commercialize the implant for reconstruction and plastic surgery markets by 2023. The product is in the pre-clinical development stage and be tested in a first clinical breast reconstruction trial in 2021.
07
08
The breakthrough innovation that Lattice Medical has developed was made possible by combining different skillsets in the textile materials industry, including through UP-tex, in connection with the medical and university team of CHU Lille and of Lille University.

Since January 2017, Lattice Medical has been in incubation at Eurasanté and receiving financial support from the Hauts-de-France region as well as from BPIFrance.
08
08

APPLICATIONS

THE MAT(T)ISSE BIOPROTHESIS:
A BIO-RESORBABLE TEC
(TISSUE ENGINEERING CHAMBER)

RESORBABLE CHAMBER

Designed and made
with 3D printed biomaterials

Adapted to the individual morphology of patients

Fully degrades
in a year

PATIENT AUTOLOGOUS ADIPOSE TISSUE GRAFTING

Vascular adipose flap tissue inlaid
over the Tissue Engineering Chamber (TEC)

Guided tissue
reconstruction

Regenerates patients’
adispose cells

The desired size is reached after just one surgery: breasts are entirely reconstructed by the patient’s tissues, and no foreign bodies are introduced.

SUBCUTANEOUS TISSUE
AND FACIAL RECONSTRUCTION

Lattice Medical also provides solutions for improving tissue engineering and regenerative medicine using 3D-printed bio-resorbable scaffolds.

Following surgery, serious burns, chronic wounds, and accidents, traumatized soft tissue needs to be repaired.

In collaboration with CHU Lille, Lattice Medical provides product design, R&D services, and various solutions for soft tissue engineering and regeneration. Alongside textile manufacturing partners, we develop textile matrixes (including Calais lace ones) that are obtained through the Leavers method.

Lattice Medical offers sub-licensing R&D contracts to manufacturers and provides pre-clinical proof-of-concept studies.

SOFT TISSUE RECONSTRUCTION PLATFORM

A new era in medical application development

Thanks to its integrated platform, Lattice Medical is able to offer innovative solutions and the opportunity for biomedical projects to explore new technological landscapes. Lattice Medical is helping manufacturers in the medical procedure industry with their transition towards 3D technology.
Lattice Medical is developing the first ISO 13485 production in clean room with 3D printing for designing personalized implantable resorbable medical devices.
This unique platform is endowed with new 3D printing and extrusion technology that is able to produce prototypes, pre-series and industrial series for R&D trials, pre-clinical and clinical studies at extremely low particular pollution levels.

More information available on https://lattice-services.com/

SERVICES

SITEDRUG

Interreg 2 Seas project “Site-Specific Drug Delivery” (Site Drug)

INTERREG TWO SEAS PROJECT : SITEDRUG

E-SHOP

FILAMENTS FOR 3D PRINTING

Want to test specific medical grade polymers for R&D purpose in 3D printing medical area such as tissue engineering, custom medical devices or 3D printed prototypes. Try our filaments for 3D printing.

NEW : See our new website dedicated to 3D Printing Filaments and 3D printing for medical devices – https://lattice-services.com/

ACCESS TO THE E-SHOP

TEAM

Justine Bax

Quality and Regulatory Affairs

Kévin ROUX

Process Engineer

Shengheng Cao

Biomedical Engineer

Dr. Pierre-Marie Danzé

Biochemist and Scientific Advisor

Jaime Destouesse-Villa

Mechanical Engineer

Marion Gradwohl

Material Engineer

Pr. Pierre Guerreschi

Plastic and Reconstructive Surgeon and Scientific Advisor

Pr. Philippe Marchetti

Biologist and Scientific Advisor

Damien Cleret

Pre-clinical Studies

Julien Payen

CEO, Co-founder

Zelzima Amelia Jordao

Biology Engineer

Jérôme Segers

Quality Engineer

Siham Bouyouaaran

Human Ressources

Chloé Gigon

Industrialisation Engineer

Mégann Le Rest

Biomaterials Engineer

Lou Pasquier

Methods Engineer

Guillaume Bruniaux

Mission Director at SIPAREX for Nord France Amorçage

Hélène Cannard

Member of the executive management at FINOVAM GESTION

François Martin

Associate Partner with Schnopp & Partner

Nicolas Blanchemain

Assistant Professor at Lille University, Biomaterials, Medical Devices and Drug Delivery

Pr. Mathias Brieu

Professor at Cal State Los Angeles, Mechanical Engineering

Pr. Xavier Garric

Professor at Montpelier University, Artificial Biopolymers

Dr. Nicolas Leymarie

Plastic and Reconstructive Surgeon, Gustave Roussy

Isabelle Martinache

Tissue referring doctor, French Biomedicine Agency

Pr. Michel Toungouz

Center for Tissue and Cell Therapy, Head of Clinic, Saint Luc and Bruxelles University

PRESS REPORT

COUSIN BIOTECH et LATTICE MEDICAL signent un accord de collaboration pour la fabrication des implants MATTISSE pour la reconstruction mammaire développés par LATTICE MEDICAL

COUSIN BIOTECH et LATTICE MEDICAL signent en présence de leurs partenaires financiers un accord de partenariat permettant à LATTICE MEDICAL de produire des pré-séries d’implants résorbables pour la reconstruction mammaire par impression 3D afin de réaliser les premiers essais cliniques. LATTICE MEDICAL installe en salle blanche ISO7 une unité de production innovante, flexible et automatisable, constituée notamment d’imprimantes 3D permettant de fabriquer des dispositifs médicaux implantables adaptés aux patientes. Cette « ferme d’impression 3D » est dédiée au développement et à la fabrication de dispositifs médicaux implantables et permettra à LATTICE MEDICAL de concevoir d’autres applications que la prothèse MATTISSE, dans le domaine de l’ingénierie tissulaire et la chirurgie reconstructrice.

Toute l’information en cliquant sur ce lien : CP partenariat COUSIN BIOTECH & LATTICE MEDICAL

LATTICE MEDICAL EST LAUREAT DU CONCOURS i-Nov

Toute l’équipe de LATTICE MEDICAL est heureuse d’annoncer que nous avons remporté le concours i-Nov dans la catégorie “Chirurgie du Futur” avec notre projet 3D BIOFARM qui nous permettra d’accélérer le développement de notre implant de reconstruction mammaire MATTISSE. Nous tenions à remercier Bpifrance et ses équipes et leurs experts pour l’excellent travail d’analyse et d’accompagnement dans notre candidature. Nous tenions également à remercier les pôles et clusters Medicen Paris Region, Eurasanté et NSL pour leur regard sur notre candidature. Enfin nous remercions également D&Consultants qui ont fourni un travail de qualité pour nous permettre de remporter ce concours. Merci et au travail !

CP LATTICE MEDICAL – Concours i-Nov

breastreconstruction 3Dprinting breastcancer

LATTICE MEDICAL REVOLUTIONNE LA RECONSTRUCTION MAMMAIRE

LATTICE MEDICAL est citée dans une double page dans la revue des alumnis de l’Ecole Polytechnique pour les 225 ans de l’école.

Source : La Jaune et la Rouge, supplément de November 2019, p58-59 Lattice Medical révolution la reconstruction mammaire

LATTICE MEDICAL IS SELECTED TO HELLOW TOMORROW DEEPTECH CHALLENGE

Among 5,000 applicants from 128 different countries, LATTICE MEDICAL have been selected as one of @hellotmrc’s Deep Tech Pioneers from their annual Global Challenge! Come and meet us at the Hello Tomorrow Global Summit in Paris on 12th-13th March, 2020!

➡️https://hello-tomorrow.org/summit/ #DeepTechPioneer #HTSummit

NEWS

NOVEMBER 2020 - LATTICE SERVICES NEW BRANCH DEDICATED TO MEDICAL 3D PRINTING

C’est avec beaucoup d’enthousiasme que LATTICE MEDICAL annonce le lancement de sa nouvelle branche d’activité 100% dédiée au développement de l’impression 3D médicale :

LATTICE SERVICES – https://lattice-services.com/

LATTICE SERVICES s’engage à vous conseiller et vous accompagner dans le développement de vos projets de R&D en vous proposant :

Une gamme de filaments 3D résorbables et implantables [PDO, PLGA, PLA/PCL),
L’extrusion personnalisée de vos filaments 3D personnalisée avec la possibilité de fonctionnaliser les matières premières

La fabrication de vos prototypes et pré-séries par impression 3D

Envie d’en savoir + ? Venez nous découvrir – https://lattice-services.com/

MAI 2020 - LATTICE MEDICAL is selected to EITHealth BridgeHead Global program

FEBRUARY 2020 - Interreg 2 Seas project “Site-Specific Drug Delivery” (Site Drug)

Aim:

The aim of this project is to develop innovative drug products, which are able to control the resulting drug distribution in the patient’s body: The drug amount at the site of action is to be optimized, and the amount that is “lost” into the rest of the human body is to be minimized. This is to be achieved by “site-specific delivery systems”, which release the drug at a controlled rate at the site of action. Thus, the therapeutic efficacy will be improved & undesired side effects reduced. This will help reducing the current cost burden on our healthcare systems due to adverse drug effects. Specifically, the project aims at developing innovative site-specific drug delivery systems for the colon, inner ear, peritoneal cavity and breast.

Expected results:

(1) Novel drug products for a safer and more efficient treatment of patients suffering from:

a) Crohn’s disease and ulcerative colitis
b) Ovarian cancer with metastases in the peritoneal cavity
c) Breast resection due to cancer
d) Hearing loss/deafness.

(2) A novel in vitro characterization method facilitating the development of “colon targeting systems” and assuring adequate quality control during production.

(3) A feasibility study, demonstrating the performance of the newly developed drug delivery systems.

Consortium partners:

University of Lille (Lead partner, Prof. Siepmann), University of Cambridge (Prof. Zeitler), Ghent University (Prof. Vervaet), University College London (Prof. Basit), Leiden University (Prof. Jiskoot), Delft University of Technology (Prof. Zadpoor), Lille University Hospital (Mrs. Leal), Lattice Medical (Dr. Payen), Prodigest (Dr. Marzorati) and the Technological Transfer Office North of France (M. Beitone).

Observer partners:

Addenbrooke’s Hospital, Dr. Reddy’s Research & Development B.V., Eurasanté, FabRx, Intract Pharma, Medtronic, Oticon Medical, Pfizer, the Queen Elizabeth The Queen Mother Hospital, and Vesale Pharma.

Funding:

This project is funded by the Interreg 2 Seas programme 2014-2020 and the European Regional Development Fund under subsidy contract “Site Drug 2S07-033”.

Project budget: 4 885 145 €; ERDF amount: 2 931 087 €; ERDF rate: 60%

Start Date: 01/01/2020; End Date: 30/09/2022